BERKELEY, Calif. — XOMA Ltd. and Kaketsuken have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new XOMA antibody phage display library, and a suite of integrated information and data management systems.
Subject to certain technical verification required under the collaboration agreement, Kaketsuken has agreed to pay XOMA $8 million and XOMA will be entitled to milestone payments and royalties on product sales.
"Antibody technologies are increasingly important in the development of novel therapeutics for a wide range of diseases so it is essential to find the best technologies and partners to maximize the chances for success," said Hiroshi Mizokami, executive director of Kaketsuken. "With XOMA's successful record of antibody candidates and drug development relationships, we are confident that they can provide us with the technologies we need to accelerate our antibody development programs."
Kaketsuken has blood plasma products, vaccines and therapeutics and is developing therapeutic solutions for infectious and other diseases.
XOMA discovers, develops and manufactures therapeutic antibodies designed to treat inflammatory, autoimmune, infectious and oncological diseases. Its proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 3AB, a biodefense anti-botulism antibody candidate.